research use only
Cat.No.S5651
|
In vitro |
DMSO
: 166.7 mg/mL
(621.38 mM)
Ultrasonicated;
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 268.27 | Formula | C11H16N4O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 24584-09-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | ICRF-187 | SMILES | CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2 | ||
Read more about storage stability stock solution CAS number SMILES
| In vitro |
Topoisomerase 2 (Top2) inhibition with dexrazoxane combined with dBET6 in HeLa cells increases DNA damage signaling at proximal time points. |
|---|---|
| In vivo |
Dexrazoxane prevents doxorubicin induced late-onset cardiomyopathy and also protected the cardiac mitochondria from acquired ultrastructural, genetic and functional damage. |
References |
(data from https://clinicaltrials.gov, updated on 2026-07-27)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07654426 | RECRUITING | Diffuse Large B-cell Lymphoma (DLBCL); Cardiotoxicity; Lymphoma |
Beth Israel Deaconess Medical Center |
2026-08-31 | PHASE2 |
| NCT03126916 | RECRUITING | Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma |
Children's Oncology Group |
2018-05-14 | PHASE3 |
| NCT04293562 | RECRUITING | Acute Myeloid Leukemia |
Children's Oncology Group |
2020-07-21 | PHASE3 |
| NCT06647953 | RECRUITING | Pleuropulmonary Blastoma |
Children's Oncology Group |
2025-03-21 | PHASE3 |
| NCT06220032 | RECRUITING | DLBCL - Diffuse Large B Cell Lymphoma |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2024-08-15 | PHASE3 |
| NCT05292664 | RECRUITING | Myelodysplastic Syndromes, de Novo; Myelodysplastic Syndromes, Secondary; Myelodysplastic Syndromes, Previously Treated; Treatment-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome; Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission; Lymphoblastic Lymphoma, in Relapse; Lymphoblastic Lymphoma, Refractory; Acute Leukemia of Ambiguous Lineage in Relapse; Acute Leukemia of Ambiguous Lineage |
Andrew E. Place, MD |
2023-03-29 | PHASE1 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.